secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2021-10-05T23:59:59+00:00
Accession:  0001493152-21-024665
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics resolves Nasdaq audit committee compliance issue, appoints Joshua Silverman
--------------------------------------------------------------------------------

- Nasdaq notified the Company of audit committee composition non-compliance from April 27 to September 30, 2021.
- Dr. Jennifer Buell resigned from the Audit Committee; Joshua Silverman appointed effective October 1, 2021.
- With Silverman's appointment, the Company is now in compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- It was later determined that Dr. Buell met independence requirements; she remains an independent board member.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315221024665/0001493152-21-024665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315221024665/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-024665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer